Search Results

You are looking at 181 - 190 of 2,734 items for :

  • Refine by Access: All x
Clear All
Full access

Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer

Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson III, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson, and Steven J. Cohen

outcome is related primarily to underlying biology or aggressive cytoreduction with or without hyperthermic intraperitoneal chemotherapy is still debated. The role of modern systemic chemotherapy and targeted therapy in early or advanced nonmucinous and

Full access

CLO22-090: Patient Characteristics, Treatment Patterns, and Clinical Outcomes of Patients With Advanced HER2-Low Breast Cancer

Alexandre Hikiji Watanabe, Connor Willis, Melissa Pavilack-Kirker, Clara Lam, Leah Park, Sandhya Mehta, Jackie Kwong, Anindit Chhibber, Hillevi Bauer, Sabrina Ilham, Diana Brixner, and David Stenehjem

in ongoing phase III clinical trials. This study aims to understand the prevalence, current treatment patterns and outcomes of HER2-low patients. Methods : This descriptive study analyzed data from a patient tumor registry in the Huntsman Cancer

Full access

Outcomes of Patients With Unfavorable Intermediate-Risk Prostate Cancer Treated With External-Beam Radiotherapy Versus Brachytherapy Alone

Neal Andruska, Benjamin W. Fischer-Valuck, Ruben Carmona, Temitope Agabalogun, Randall J. Brenneman, Hiram A. Gay, Jeff M. Michalski, and Brian C. Baumann

BT + ADT Relative to EBRT Alone Given the significant potential selection bias for EBRT versus BT, IPTW was used to balance covariables that influenced both treatment allocation and outcomes, and weight-adjusted Cox regression was used to

Full access

HSR21-076: Valued Outcomes in the Cancer Experience (VOICE™): Developing and Validating a Measure of Patient Experience

Alexandra K. Zaleta, Erica E. Fortune, Melissa F. Miller, Branlyn W. DeRosa, Joanne S. Buzaglo, Karen Hurley, Mitch Golant, Sara Goldberger, Bruce Rapkin, Lillie D. Shockney, Jemeille Ackourey, and Kelly A. Clark

Background: Despite recognition that patient perspectives should inform cancer care, validated measures that meaningfully capture the patient experience across the cancer continuum remain lacking. We developed Valued Outcomes in the Cancer

Full access

HSR20-094: Treatment Patterns, Healthcare Resource Utilization and Patient-Reported Outcomes for Patients Diagnosed With Small Cell Lung Cancer

Junji Lin, Santosh Gautam, Nan Hu, Debra Wertz, Gboyega Adeboyeje, and Sumesh Kachroo

) and patient-reported outcomes (PROs). This study describes patient characteristics, treatment patterns, HCRU and PROs for these pts in community oncology settings. Methods: Retrospective medical records data from adults diagnosed with eSCLC between 1

Full access

HSR20-081: The Direct Referral Unit: Clinical Outcomes and Experience With a Specialized Urgent Care Center for Oncology Patients

Christopher D'Avella, Peter Whooley, Emily Milano, Brian Egleston, Martin Edelman, James Helstrom, Kenneth Patrick, and Jessica Bauman

admissions. Fox Chase Cancer Center (FCCC) developed an urgent care center, the direct referral unit (DRU), in 2012. We sought to characterize the experience of the DRU and its impact on clinical outcomes and utilization. Methods: We abstracted data for

Full access

Introduction to the Cancer Center Cessation Initiative Working Groups: Improving Oncology Care and Outcomes by Including Tobacco Treatment

The Cancer Center Cessation Initiative Coordinating Center and Expert Advisory Panel

smokers at the time of diagnosis. 5 Although compelling data have shown that quitting smoking after a cancer diagnosis leads to better health and quality of life outcomes, a 2009 survey reported that only 38% of NCI Cancer Centers recorded smoking as a

Full access

A Survey of the National Comprehensive Cancer Network on Approaches Toward Addressing Patients’ Transportation Insecurity

Krisda H. Chaiyachati, Diana Krause, Jessica Sugalski, Evan M. Graboyes, and Lawrence N. Shulman

widened racial and income disparities in cancer treatment outcomes. 19 – 21 Although national organizations such as the National Academies of Sciences, Engineering, and Medicine have identified transportation insecurity as a key social risk factor, 22

Full access

CLO22-035: Treatment Outcome of Ruxolitinib and Decitabine Combination Chemotherapy Among Transplant Ineligible Advanced Stage Myeloproliferative Neoplasm: A Meta-analysis

Jacqueline Agustin and Ma. Rosario Irene D. Castillo

not eligible for transplant, hence chemotherapy is a frequently chosen alternative. This meta-analysis sheds light on treatment outcomes of advanced stage myeloproliferative neoplasm patients treated with combination decitabine and ruxolitinib

Full access

CLO23-025: Comparison of Outcomes Using NCCN Classification in Two Concurrent Phase III Trials in Intermediate and High Risk Prostate Cancer: Long-Term Data

Abdenour Nabid, Nathalie Carrier, Eric Vigneault, André-Guy Martin, Thu Van Nguyen, Jean-Paul Bahary, Peter Vavassis, Marc-André Brassard, Sylvie Vass, Boris Bahoric, Robert Archambault, Francois Vincent, Redouane Bettahar, Marie Duclos, Derek Wilke, and Luis Souhami

Purpose/Objective(s): To compare the magnitude of differences in outcomes between intermediate and high risk prostate cancer (IRPC – HRPC) using NCCN classification in two concurrent phase III trials performed in the same population. Materials